Novavax Inc
Research Novavax Inc (NVAX) on Bullrun: market cap USD 1.54B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNVAX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.54B
- Financial periodFY2025
- RevenueUSD 1.12B
- Revenue growth64.7%
- Net incomeUSD 440.30M
- Gross margin93.5%
Valuation Snapshot
latest market cap is USD 1.54B.
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine.
Frequently asked questions
What is Novavax Inc's market cap?
Novavax Inc's market capitalization is USD 1.54B.
What does Novavax Inc do?
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine;